Joshua Friedman

Company: Spyre Therapeutics

Job title: SVP Clinical Development

Seminars:

Advancing Combination Therapies to Change the Treatment Paradigm in IBD 4:30 pm

Scientific and clinical rationale for targeting ɑ4β7, TL1A, and IL-23 pathways in IBD therapy Nonclinical data demonstrating enhanced efficacy and extended half-life of biologics for combination treatments Addressing the natural questions around patient selection for combination therapies: early hypotheses and future directionsRead more

day: Day One